---
title: Reduce tremor and improve movement
nct_id: NCT06400017
phase: NA
status: RECRUITING
sponsor: Beijing Tiantan Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06400017"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06400017"
last_fetched: "2026-05-10T14:05:05.416Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce tremor and improve movement

**Goal (in five words):** Reduce tremor and improve movement

**Official Title:** Mechanism and Application of Deep Brain Stimulation in the Treatment of Parkinson's Disease

**Trial ID:** [NCT06400017](https://clinicaltrials.gov/study/NCT06400017)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Beijing Tiantan Hospital
- **Target Enrollment:** 60 participants
- **Start Date:** 2024-07-01
- **Completion Date:** 2025-12-31
- **Conditions:** Parkinson's Disease and Parkinsonism
- **Interventions:** microelectrode stimulation of DBS
- **Intervention Types:** DEVICE

## Summary For Families

The trial aims to clarify how deep brain stimulation of the subthalamic nucleus controls Parkinson's motor symptoms and to evaluate the mechanism and application of an MRI-compatible dual-channel DBS system. It uses microelectrode-guided bilateral STN DBS with a 3.0T-compatible G106R/G106RS device, delivering continuous electrical pulses to rebalance abnormal motor circuits, which can reduce tremor, rigidity, and slowness and often lets people lower their levodopa dose. Participants should be adults 50 to 70 years old with typical Parkinson's for less than 20 years who plan bilateral STN DBS, have no major cognitive impairment (MMSE ≥24, MoCA ≥18), and have no medical or MRI contraindications to surgery.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 70 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Voluntarily participate in the clinical study and sign the informed consent;
* Age 50-70 years old, gender unlimited;
* The clinical diagnosis is consistent with typical PD, and the medical history is less than 20 years;
* Patients who intend to use 3.0T magnetic resonance compatible dual-channel DBS device (G106R or G106RS, Beijing Pinchi Company) for bilateral subthalamic nucleus DBS surgery to control PD symptoms;
* MRI excluded patients with obvious structural changes;
* The visual acuity and hearing of the subjects were basically normal, and the compliance was good, and they could complete the tasks listed in the experimental scheme in accordance with the standards.

Exclusion Criteria:

* Serious mental, cognitive and psychological disorders, unable to sign informed consent or cooperate with the operation and various tasks;
* There are contraindications for neurosurgery, such as hydrocephalus, cerebral atrophy, cerebrovascular sequelae, heart disease and other cardiovascular and cerebrovascular diseases;
* There are concomitant diseases that seriously affect health, such as tumors, serious abnormalities of liver and kidney function (indexes more than 3 times normal);
* There is intracranial space occupation, cerebrovascular disease, mental illness, other neurological diseases, claustrophobia, or there is an implant in the body, which affects the nuclear magnetic scan;
* The results of the Mini-Mental State Scale (MMSE) \<24 or the Montreal Cognitive Assessment Scale (MoCA) \<18 in the preoperative assessment, or the results of other scales indicate the presence of severe dementia.
```

## Locations (1)

- Beijing Tiantan Hospital, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Shi Lin — (CONTACT) — 86 010 15210466780 — shilin2015@foxmail.com

## Central Contacts

- lin shi, M.D. — (CONTACT) — 008615210466780 — shilin2015@foxmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06400017*  
*HTML version: https://parkinsonspathways.com/trial/NCT06400017*  
*Source data: https://clinicaltrials.gov/study/NCT06400017*